HIMS boasts a partnership with a leading US manufacturer of generic and 503B compounded injectable medications, although this partner remains unnamed
Retatrutide (LY3437943) is a synthetic 39-amino acid triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, commonly referenced in scientific literature for metabolic research, obesity mechanism studies, hepatic steatosis models, and energy expenditure pathway investigations in laboratory and preclinical environments
Despite these advances, critical gaps remain: non-coding RNAs (ncRNAs) such as long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs) have only been sporadically implicated in this network (e.g., miR-125a targeting SLC7A11 in diabetic nephropathy), and their cell type-specific roles in renal ferroptosis remain largely uncharacterized
Compensated for usage rights